Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.66 |
| ▸ | CNR2 | P34972 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334779 | 0.93 | CNR1 (0.56) | CNR1CNR2ALDH1A1F10NPC1 | |
| SCHEMBL4333044 | 0.89 | CNR1 (0.66) | CNR1CNR2ALDH1A1F10NPC1 | |
| SCHEMBL4327321 | 0.89 | CNR1 (0.63) | CNR1CNR2ALDH1A1F10 | |
| SCHEMBL4334472 | 0.88 | CNR2 (0.68) | CNR1CNR2ALDH1A1F10NPC1 | |
| SCHEMBL4327707 | 0.87 | CNR1 (0.73) | CNR1CNR2NPC1RAB9AHTT | |
| SCHEMBL4324246 | 0.87 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL4324652 | 0.87 | CNR2 (0.73) | CNR1CNR2F10NPC1RAB9A | |
| SCHEMBL4331188 | 0.86 | CNR1 (0.59) | CNR1CNR2ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4328048 | 0.83 | CNR1 (0.70) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL4321808 | 0.83 | CNR1 (0.65) | CNR1CNR2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885ALDH1A1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.